Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James W Chu

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Chest|November 12, 2002
High prevalence of autoimmune thyroid disease in pulmonary arterial hypertensionJames W Chu, Peter N Kao, John L Faul, et al.
Clinical Medicine & Research|March 3, 2009
The effect of an inhaled corticosteroid on glucose control in type 2 diabetesJohn L Faul, Sandra R Wilson, James W Chu, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitusFahim Abbasi, James W Chu, Tracey McLaughlin, et al.
Diabetes & Vascular Disease Research|November 25, 2005
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjectsJames W Chu, Fahim Abbasi, Cynthia Lamendola, et al.
Diabetes|February 28, 2004
Discrimination between obesity and insulin resistance in the relationship with adiponectinFahim Abbasi, James W Chu, Cindy Lamendola, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes CareNella Bieszk, Michael Grabner, Wenhui Wei, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapiesWenhui Wei, Erin Buysman, Michael Grabner, et al.
Diabetes|July 28, 2005
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individualsSun H Kim, Fahim Abbasi, James W Chu, et al.
The American Journal of Cardiology|January 12, 2005
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemiaCindy Lamendola, Fahim Abbasi, James W Chu, et al.
Journal of the American College of Cardiology|July 6, 2004
Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic linkRonald M Witteles, W H Wilson Tang, Aamer H Jamali, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Chest|November 12, 2002
High prevalence of autoimmune thyroid disease in pulmonary arterial hypertensionJames W Chu, Peter N Kao, John L Faul, et al.
Clinical Medicine & Research|March 3, 2009
The effect of an inhaled corticosteroid on glucose control in type 2 diabetesJohn L Faul, Sandra R Wilson, James W Chu, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitusFahim Abbasi, James W Chu, Tracey McLaughlin, et al.
Diabetes & Vascular Disease Research|November 25, 2005
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjectsJames W Chu, Fahim Abbasi, Cynthia Lamendola, et al.
Diabetes|February 28, 2004
Discrimination between obesity and insulin resistance in the relationship with adiponectinFahim Abbasi, James W Chu, Cindy Lamendola, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes CareNella Bieszk, Michael Grabner, Wenhui Wei, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapiesWenhui Wei, Erin Buysman, Michael Grabner, et al.
Diabetes|July 28, 2005
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individualsSun H Kim, Fahim Abbasi, James W Chu, et al.
The American Journal of Cardiology|January 12, 2005
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemiaCindy Lamendola, Fahim Abbasi, James W Chu, et al.
Journal of the American College of Cardiology|July 6, 2004
Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic linkRonald M Witteles, W H Wilson Tang, Aamer H Jamali, et al.
Pageof 2